AZ-BMS rumors, Replimune, psychedelics — a BioCentury podcast

BioCentury’s analysts on mega-merger skepticism, regulatory roller-coasters, and psychedelics’ next frontier in depression

Rumors flew this weekend about a mega-merger of AstraZeneca and Bristol Myers — but would such a deal make sense? On the latest BioCentury This Week podcast, BioCentury’s analysts explain why they aren’t buying it.

The team also discusses what lessons can be learned from the regulatory roller-coaster ride of Replimune’s RP1 vusolimogene oderparepvec and psychedelic therapies’ inflection point in treating depression.